Cancer Biological Therapy Market Research- Asia Pacific  Forecast till 2027

Asia Pacific Cancer Biological Therapy Market Information: By Type (Monoclonal Antibodies, Interferons, Interleukins, Cancer Growth Inhibitors, Gene Therapy, Colony-Stimulating Factors, Targeted Therapy, Cancer Vaccines and others), By Phases (Phase I, Phase II, Phase III) By End Users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast till 2027

ID: MRFR/Pharma/2980-HCR | February 2021 | Region: Global | 50 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario
Cancer is the leading and the second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and others. Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor, such therapies known as; cancer targeted therapies.

The major driving factors for Asia Pacific cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries, etc. Additionally, less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that these methods also show its counter effects on body. The side effects may include, loss of hair, weakened immune system, and such others depending upon the type, and phase of cancer. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%. Owing to low level of side effects and high success rate of this therapy, the market is expected to grow rapidly. However, high cost of the treatment may restrain the market growth.

The Asia Pacific cancer biological therapy market is expected to grow at a CAGR of 5.5% during the forecasted period.
Figure 1: Asia Pacific cancer biological therapy market, by types

APAC Cancer Biological Therapy Market

  Sources: Annual reports, Press release, White paper, Company Presentation


Key Players
The leading market players in the Asia Pacific cancer biological therapy market include Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India)

Asia Pacific cancer biological therapy market is segmented into types, phases, and end users.

On the basis of types the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines, and others. On the basis of phases, the market is segmented into phase I, phase II, and phase III.

On the basis of end users, the market is segmented into hospitals & clinics, cancer research centers, laboratories, and others.

Market Assessment
APAC Cancer Biological Therapy Market-

Sources: Annual reports, World Health Organization (WHO), White paper, Company Presentationa 

Regional Analysis
China dominates the Asia Pacific cancer biological therapy market owing to increasing prevalence of cancer.  Increasing adoption of smoking by people, rapid research & development and presence rapidly developing economy in this region fuel the growth of the market in Asia Pacific. Japan and Australia are other major contributor to the market growth in this region.

Intended Audience

  • Pharmaceutical Companies

  • Pharmaceutical Suppliers

  • Cancer Research Organizations

  • Potential Investors

  • Key Executive (CEO and COO) and Strategy Growth Manager

  • Research Companies


Frequently Asked Questions (FAQ) :

The projected CAGR of Asia Pacific Cancer Biological Therapy Market would 5.5% during the forecast period of 2018-2023.

The Asia Pacific Cancer Biological Therapy Market could be deterred by the high cost involved in the process.

The players are F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Novartis AG (Switzerland), Amgen Inc. (US), Pfizer (US), Intas Pharmaceuticals Ltd. (India), Eli Lilly and Company (US), EnGeneIC (Australia), Celgene (US), and Sun Pharmaceutical Industries Ltd. (India).

Asia Pacific Cancer Biological Therapy Market segmented by types into interferon, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors, gene therapy, cancer vaccines, targeted therapy, and others.

Asia Pacific Cancer Biological Therapy Market segmented by end users into laboratories, cancer research centers, hospitals & clinics, and others.

Table of Contents
1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6. Asia Pacific Cancer Biological Therapy Market, by Type

6.1 Monoclonal Antibodies

6.2 Interferons

6.3 Interleukins

6.4 Cancer Growth Inhibitors

6.5 Gene Therapy

6.6 Colony-Stimulating Factors

6.7 Targeted Therapy

6.8 Cancer Vaccines

6.9 Others

7. Asia Pacific Cancer Biological Therapy Market, by Phases

7.1 Phase I

7.2 Phase II

7.3 phase III

8. Asia Pacific Cancer Biological Therapy Market, by Phases

8.1 Hospitals & Clinics

8.2 Cancer Research Centers

8.3 Laboratories

8.4 Others

9. Asia Pacific Cancer Biological Therapy Market, by Regions

9.1 Introduction

9.1.1 Japan

9.1.2 China

9.1.3 India

9.1.4 Australia

9.1.5 Republic of Korea

9.1.6 Rest of Asia Pacific

10. Competitive Landscape

10.1 Major Strategies Adopted By Market Players

10.1.1 Strategic Partnership

10.1.2 Merger & Acquisition

11 Company Profile

11.1 Merck & Co., Inc.

11.1.1 Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.2 F. Hoffmann-La Roche Ltd

11.2.1 Overview

11.2.2 Product Overview

11.2.3 Financials

11.2.4 Key Developments

11.3 Novartis AG

11.3.1 Overview

11.3.2 Product Overview

11.3.3 Financials

11.3.4 Key Development

11.4 Amgen Inc.

11.4.1 Overview

11.4.2 Product Overview

11.4.3 Financials

11.4.4 Key Developments

11.5 Bristol-Myers Squibb

11.5.1 Overview

11.5.2 Product Overview

11.5.3 Financials

11.5.4 Key Developments

11.6 Celgene

11.6.1 Overview

11.6.2 Product Overview

11.6.3 Financials

11.6.4 Key Developments

11.7 Eli Lilly and Company

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.8 EnGeneIC

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.9 Intas Pharmaceuticals Ltd.

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.10 Others

12 Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix